Innovation

Analgesic Effects of sEH Inhibitors in the Presence of Increased cAMP Levels

University of California System: University of California, Davis - UC Davis
posted on 07/01/2009

Brief description unavailable

Suggested Uses

  • The combined administration of EETs, sEH inhibitors, or EETs and sEH inhibitors, with agents that increase intracellular cAMP levels can be used for the treatment and management of acute and chronic pain.
  • The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP may be used to reduce the number or delay the onset of seizures.
  • EETs and sEH inhibitors can be used to alleviate symptoms of diseases that are associated with naturally occurring increased levels of intracellular cAMP. For example, increased levels of intracellular cAMP are known to occur during withdrawal from opioids. EETs, sEH inhibitors, or both can be administered during withdrawal to alleviate withdrawal symptoms.

Advantages

  • The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP can be used to manage and treat pain.
  • The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors can be administered to patients with a naturally occurring increased cAMP level to alleviate pain.
  • The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP can be used as a sedative, and can also facilitate recovery from anesthesia.
  • The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP may be used to delay the onset of seizures.


Innovation Details
 

Detailed Description

Analgesic compounds have very wide applications in human and animal health, one of which is pain control.  In mammals, cytochrome P450 epoxygnases metabolize arachidonic acid and yields epoxy-eicosatrienoic acids (EETs).  The EETs are thereafter metabolized by soluble epoxide hydrolase (sEH).  EETs and inhibitors of sEH have previously been shown to be effective in reducing pain when administered systemically or topically.


Researchers at the University of California, Davis have discovered that the analgesic effect of EETs and sEH inhibitors requires the presence of increased intracellular levels of cyclic adenosine monophosphate (cAMP).  Thus, the co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP will be useful in increasing analgesia.

File Number: 18952 


IP Protection

Copyright: ©2009-2010, The Regents of the University of California

License Online

This innovation currently is not available for online licensing. Please contact Barbara Boczar at University of California System: University of California, Davis - UC Davis for more information.

request more info
People

Case Manager:

Icon_avatar Barbara Boczar

Innovations (35)

Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

4,043 members 12,268 innovations 109 organizations

Browse

W. Mark Crowell - University of North Carolina at Chapel Hill

"The iBridge Network makes it easier to move innovations and research tools into the hands of potential partners. It has already helped us find collaborators and developers for important gene therapy treatment of orphan diseases."  read more...